172 related articles for article (PubMed ID: 20696919)
1. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.
Nuber N; Curioni-Fontecedro A; Matter C; Soldini D; Tiercy JM; von Boehmer L; Moch H; Dummer R; Knuth A; van den Broek M
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15187-92. PubMed ID: 20696919
[TBL] [Abstract][Full Text] [Related]
2. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.
Curioni-Fontecedro A; Nuber N; Mihic-Probst D; Seifert B; Soldini D; Dummer R; Knuth A; van den Broek M; Moch H
PLoS One; 2011; 6(6):e21418. PubMed ID: 21738656
[TBL] [Abstract][Full Text] [Related]
3. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
[TBL] [Abstract][Full Text] [Related]
4. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis.
Güre AO; Stockert E; Arden KC; Boyer AD; Viars CS; Scanlan MJ; Old LJ; Chen YT
Int J Cancer; 2000 Mar; 85(5):726-32. PubMed ID: 10699956
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
[TBL] [Abstract][Full Text] [Related]
7. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
8. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
[TBL] [Abstract][Full Text] [Related]
9. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C; Zustin J; Jacobsen F; Luetkens T; Kröger N; Schilling G; Bokemeyer C; Sauter G; Atanackovic D; Marx A
Exp Mol Pathol; 2010 Oct; 89(2):175-81. PubMed ID: 20621094
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T cell responses to SSX-4 in melanoma patients.
Ayyoub M; Merlo A; Hesdorffer CS; Rimoldi D; Speiser D; Cerottini JC; Chen YT; Old LJ; Stevanovic S; Valmori D
J Immunol; 2005 Apr; 174(8):5092-9. PubMed ID: 15814740
[TBL] [Abstract][Full Text] [Related]
12. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
13. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.
Manici S; Sturniolo T; Imro MA; Hammer J; Sinigaglia F; Noppen C; Spagnoli G; Mazzi B; Bellone M; Dellabona P; Protti MP
J Exp Med; 1999 Mar; 189(5):871-6. PubMed ID: 10049951
[TBL] [Abstract][Full Text] [Related]
14. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck.
Prasad ML; Jungbluth AA; Patel SG; Iversen K; Hoshaw-Woodard S; Busam KJ
Head Neck; 2004 Dec; 26(12):1053-7. PubMed ID: 15515159
[TBL] [Abstract][Full Text] [Related]
15. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
16. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
19. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Brusic V; Sidney J; Sette A; Logan TF; Kasamon YL; Slingluff CL; Kirkwood JM; Storkus WJ
Clin Cancer Res; 2003 Mar; 9(3):947-54. PubMed ID: 12631591
[TBL] [Abstract][Full Text] [Related]
20. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.
Kudela P; Sun Z; Fourcade J; Janjic B; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2011 Jan; 186(1):312-22. PubMed ID: 21131422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
